Conference abstract · 24 Apr 2017
Conference abstractPublished 12 Nov 2013
Automation in validated environments
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Challenge: A complicated system with a number of monolithic pieces, compliant with PDMA and 21 CFR Part 11 regulations had to be developed in a short time with a small team was just the beginning of the challenges. Missing the date would have put the entire business at risk owing to resource constraints; also the system in use was not able to support the demand coming in from the clients. Additionally, the nature of the business requires all validation documentation to meet the expectations of every client, which includes many of the top 10 pharmaceuticals. Any high impact failure in operational qualification stage would have potentially reset the progress of the project. Approach: In order to mitigate the issues and bugs that will arise and also to meet the schedule, two steps were taken. One, regulations team was brought to work very closely with the developers to avoid high risk bugs. Second, many test scripts that were to be executed manually by the validation team were automated. Results: Following the approach stated above, operational qualification of the system was completed in 10 days as compared to the initial estimate of 25 days. The approach not only proved fruitful to meet the deadline but also made work more fun and eliminated a lot of manual work. Conclusion: Manual execution of protocols is not only time consuming but also lead to human errors which could be very expensive depending on its implications. To use automation in the regulated environments needs money and time to be invested in the beginning, however, if the result is a robust execution process with reduced delivery time then it is worth it.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 12 Nov 2013
What really matters to FDA and why? A comprehensive review & analysis of FDA enforcement action on automated system validation
Conference abstract · 21 Oct 2013
A cost-effective and practical approach to risk-based computerized system validation (CSV) for pharmaceutical and medical devices regulated environments
Conference abstract · 25 Mar 2019
A 3D-printed automated sample storage unit for sporadic sampling in inaccessible aquatic environment
Conference abstract · 25 Mar 2019
A 3D-printed automated sample storage unit for sporadic sampling in innaccessible aquatic environment
More from this journal
The newest in Journal of Developing Drugs.
Research article · 17 Jul 2026
Effects of a Food-Derived GLP-1 Formula on Endogenous GLP-1 Secretion and Appetite Responses: A Randomized Double-Blind Crossover Study
Commentary · 4 Feb 2026
Vaccine Development and Global Disease Prevention
Commentary · 4 Feb 2026
Transforming Drug Development Through Pharmaceutical Biotechnology
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Developing Drugs
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Abitha Sundararajan”

